The Netherlands
Digi.Bio, founded in 2017, is at the forefront of innovation in the convergence of artificial intelligence and biotechnology. Based in The Netherlands, with its headquarters in Amsterdam, this startup is changing the landscape of therapeutic development through its AI-driven, lab-on-a-chip technology.
Their platform focuses on single-cell analysis, allowing for dynamic and high-content real-time monitoring of therapy performance. This capability provides groundbreaking spatial and temporal insights into treatment behaviors, a crucial step in the development of breakthrough therapies. Operating out of BSL-2 laboratories at Leiden Bio Science Park, Digi.Bio's technology grants a digital, single-cell representation of therapy responses that can significantly accelerate therapeutic innovations.
Although the company has yet to announce its latest funding rounds or investor partnerships, Digi.Bio's technological prowess within the AI, Biotechnology, and Information Technology sectors positions it as a promising opportunity for investors seeking a transformative impact in medical and biotech advancements.
